SCHEMBL2633667

SCHEMBL2633667

Cc1cc(S(C)(=O)=O)c(C)cc1Cl

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SOD1 P00441 1/20 0.47
L3MBTL1 Q9Y468 2/20 0.45
HSD17B1 P14061 1/20 0.45
HSD17B2 P37059 1/20 0.45
KMT2A Q03164 3/20 0.43
GRIN2D O15399 1/20 0.42
GRIN3B O60391 1/20 0.42
GRIN1 Q05586 1/20 0.42
GRIN2A Q12879 1/20 0.42
GRIN2B Q13224 1/20 0.42
GRIN2C Q14957 1/20 0.42
GRIN3A Q8TCU5 1/20 0.42
CA12 O43570 2/20 0.41
CA1 P00915 2/20 0.41
CA2 P00918 2/20 0.41
CA9 Q16790 2/20 0.41
HTT P42858 1/20 0.41
GLA P06280 1/20 0.41
TSHR P16473 1/20 0.41
MEN1 O00255 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20096113 0.91 L3MBTL1 (0.45) SOD1L3MBTL1HSD17B1HSD17B2KMT2A
SCHEMBL8056461 0.84 L3MBTL1 (0.47) SOD1L3MBTL1HSD17B1HSD17B2CA12
SCHEMBL9462404 0.84 SOD1 (0.49) SOD1L3MBTL1HSD17B1HSD17B2KMT2A
SCHEMBL29707985 0.82 SOD1 (0.47) SOD1L3MBTL1HSD17B1HSD17B2KMT2A
SCHEMBL152556 0.82 SOD1 (0.47) SOD1L3MBTL1HSD17B1HSD17B2KMT2A
SCHEMBL15478488 0.80 RAPGEF4 (0.52) L3MBTL1HSD17B2KMT2AHTTTSHR
SCHEMBL6038490 0.80 CA2 (0.56) SOD1L3MBTL1HSD17B1HSD17B2KMT2A
SCHEMBL10788348 0.80 HSD17B1 (0.47) SOD1HSD17B1HSD17B2KMT2ACA12
SCHEMBL6038486 0.80 SOD1 (0.46) SOD1L3MBTL1HSD17B1HSD17B2KMT2A
SCHEMBL8404548 0.78 L3MBTL1 (0.42) L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024137813-A1 MODULATORS OF MITOCHONDRIAL DNA REPLICATION PRETZEL THERAPEUTICS, INC. (US) 2024-06-27 WO disclosed
US-10005732-B2 Potent non-urea inhibitors of soluble epoxide hydrolase THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2018-06-26 US disclosed
US-9175285-B2 Potent non-urea inhibitors of soluble epdxide hydrolase THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2015-11-03 US disclosed
US-20140349368-A1 POTENT NON-UREA INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2014-11-27 US disclosed
US-8653273-B2 Potent non-urea inhibitors of soluble epoxide hydrolase THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2014-02-18 US disclosed
EP-2403854-B1 SULFONYLATED TETRAHYDROAZOLOPYRAZINES AND THEIR USE AS MEDICINAL PRODUCTS GRUENENTHAL GMBH (DE) 2013-09-11 EP disclosed
US-8158628-B2 Sulfonylated 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine compounds and their use as pharmaceuticals GRUENENTHAL GMBH (DE) 2012-04-17 US disclosed
US-20100234387-A1 Sulfonylated Tetrahydroazolopyrazines and their Use as Pharmaceuticals GRUENETHAL GMBH (DE) 2010-09-16 US disclosed
EP-1703905-B1 INDOLE DERIVATIVES AND USE THEREOF AS KINASE INHIBITORS IN PARTICULAR IKK2 INHIBITORS SMITHKLINE BEECHAM CORP (US) 2008-11-12 EP disclosed
US-20080269200-A1 Indole Derivatives and Use Thereof as Kinase Inhibitors in Particular Ikk2 Inhibitors SMITHKLINE BEECHAM CORPORATION (US) 2008-10-30 US disclosed
US-20080269200-A1 Indole Derivatives and Use Thereof as Kinase Inhibitors in Particular Ikk2 Inhibitors SMITHKLINE BEECHAM CORPORATION (US) 2008-10-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100234387-A1 Sulfonylated Tetrahydroazolopyrazines and their Use as Pharmaceuticals BDKRB1, BDKRB2, KCNB1 SOD1 2717/4885L3MBTL1 4053/4885HSD17B1 3092/4885
US-20140349368-A1 POTENT NON-UREA INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE EPHX1, EPHX2, ECE1 SOD1 2448/4885L3MBTL1 4505/4885HSD17B1 713/4885
US-20080269200-A1 Indole Derivatives and Use Thereof as Kinase Inhibitors in Particular Ikk2 Inhibitors NFKBIA, IKBKB, IDO2 SOD1 3846/4885L3MBTL1 3823/4885HSD17B1 1962/4885
US-10005732-B2 Potent non-urea inhibitors of soluble epoxide hydrolase EPHX1, EPHX2, ECE1 SOD1 2448/4885L3MBTL1 4505/4885HSD17B1 713/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.